摘要
目的 :观察ELF方案治疗晚期胃癌的近期疗效和患者耐受性。方法 :32例晚期胃癌病人用ELF方案治疗 :依托泊苷 (VP 16 ) 10 0mg静脉点滴 ,第 1— 3天 ;醛氢叶酸 (CF) 10 0— 30 0mg静脉点滴 ,第 1— 3天 ;氟尿嘧啶 (5 FU) 75 0— 10 0 0mg静脉点滴 ,第 1— 3天 ;3周为 1疗程。结果 :总缓解率为 37.5 % (12 32 ) ,完全缓解率 (CR)为 3.1%(1 32 ) ,部分缓解率 (PR)为 34.4% (11 32 )。主要毒副反应为骨髓抑制和脱发。白细胞减少Ⅰ—Ⅱ度发生率 6 8.8% ,Ⅲ—Ⅳ度发生率 12 .5 %。血红蛋白及血小板减少发生率分别为 2 1.8%和 35 .1%。脱发发生率为 10 0 %。其他毒副反应少见。结论 :ELF方案治疗晚期胃癌的疗效肯定 。
Purpose:To observe the response and tolerance to the regimen of etoposide,folinic acid and fluorouracil (ELF) in advanced gastric cancer. Methods:Thirty two patients with advanced gastric cancer received chemotherapy of ELF regimen(VP 16 100 mg iv d 1—3 ,CF 100—300 mg iv d 1—3,5 FU 750 1 000 mg iv d 1—3 Results:The overall response rate was 37.5% (12/32) and complete response rate was 3.1% (1/31), the partial response rate was 33.4% (11/32). The main toxicity was myelosuppression and alopecia. Leukopenia was observed in 81.6% of the patients, but grade 3 and 4 in only 12.5%. Anemia and throbopenia was observed in 21.8% and 35.1% of the patients respectively, alopecia in 100%. Other side effects were uncommon. Conclusions:This study shows that the regimen of ELF is effective and tolerable for treatment of advanced gastric cancer. [
出处
《中国癌症杂志》
CAS
CSCD
2001年第1期61-62,共2页
China Oncology
